Financing / Venture Capital

In the current tough funding environment, companies need attorneys experienced with financing transactions. Life Sciences Law attorneys have regularly represented companies, founders, venture capital firms, banks and investment banks in connection with investments in life sciences company. These investments have ranged from start-up capital to private offerings of both equity and debt securities for established companies to initial public offerings. We have also assisted companies in structuring and obtaining research grants from governmental agencies and non-profit organizations. Some of our recent transactions include:

Recent venture capital transactions, worth on aggregate of approximately $200 million, include:

• Series A Convertible Preferred Stock in a company processing health insurance claims
• Series A Convertible Preferred Stock in a company specializing in genetically reengineered pest control resistant crops;
• Series A Convertible Preferred Stock in a company developing specialty drug products;
• Series A Preferred Stock in company selling used laboratory and telecommunications equipment;
• Series B Preferred Stock in a company developing an expert system for the management of treatments for HIV;
• Series B Convertible Preferred Stock in a chemistry analysis and testing biotechnology company;
• Series B Preferred Stock in a research services company
• Series A and B Convertible Preferred in a company developing a treatment for heart failure
• Series A and B Convertible Preferred in a company developing therapeutics for hemophilia and other bleeding disorders
• Sale of a profits interest in a rFIX drug
• Sales of convertible notes as bridge financing
• Completion of several transactions with venture philanthropists, including the Muscular Dystrophy Association, the Musculoskeletal Transplant Foundation and the ALS Foundation